Glucose control during kidney transplantation in type 1 diabetes patient on sensor augmented pump: a case report
The worldwide incidence of type 1 diabetes (T1D) is quite variable and increasing by approximately 3% each year globally, where in high-income countries, 7–12% of all diabetes population is estimated to have type 1 diabetes . Diabetes is the leading cause of end-stage renal disease (ESRD) in the Western world and long-term complications due to diabetes are a major cause of disability and reduced quality of life. Continuous subcutaneous insulin infusion (CSII) is an established model for mimicking physiological insulin delivery, which can assist in achieving near-normal glucose levels with minimizing the risk of hypoglycemia and preventing or delaying diabetes complications. The Center for insulin pump and glucose sensor at University Clinic of Endocrinology in Skopje has managed more than 180 patients with CSII over the last 10 years. Our recent publication assessing long-term CSII treatment reported improved and sustained glucose control with a reduction of HbA1c...
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from the patient.
- 1.International Diabetes Federation (2015) IDF Diabetes Atlas, 7 th edn. International Diabetes Federation, BrusselsGoogle Scholar
- 5.Peters AL, Ahmann AJ, Battelino T et al. (2016) Diabetes technology—continuous subcutaneous insulin infusion therapy and continuous glucose monitoring in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 101(11):3922–3937. https://doi.org/10.1210/jc.2016-2534 CrossRefPubMedGoogle Scholar